Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma

Rodriguez, Jefferson Antonio Buendia; Patiño, Diana Guerrero; Cossio-Giraldo, Yamith Eutimio

doi:10.1080/02770903.2021.1984527

Cited by 15 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the same way, in patients with severe asthma and hyper-IgE, omalizumab, under the current costs of this drug, is not cost-effective, and only with a 41% reduction in its price, the estimated ICER could be lower than the WTP in Colombia. 24 The problem of high costs of biological drugs is not exclusive to developing countries; also, in the United States; despite the entry into the market of biosimilars, costs have not dropped significantly, generating a great economic burden for health systems. [25][26][27] With the evidence presented here, the effectiveness and safety of biological drugs such as dupilumab is not in doubt.…”

Section: Discussionmentioning

confidence: 99%

Dupilumab in children with moderate‐to‐severe asthma: A cost utility analysis

Buendía

Patiño

2022

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

Introduction Dupilumab is an effective and safe medicine for the management of severe asthma. Due to its high cost, concerns are generated regarding its cost‐effectiveness. This study aimed to estimate the cost‐utility of dupilumab plus standard of care (SoC) versus SoC alone in children between 6 and 11 years old with severe asthma and eosinophilic phenotype. Methods A Markov‐type model was developed to estimate costs and health outcomes of a simulated cohort of pediatric patients with persistent asthma treated over a 6‐year period. To determine the robustness of the model deterministic and probabilistic sensitivity analyses were conducted. Results The quality‐adjusted life‐years (QALYs) per patient estimated were 0.85 with dupilumab and 0.84 with SoC. The total mean of discounted costs per patient per cycle were US$ 379 for dupilumab and US$ 19 for SoC. The incremental cost‐effectiveness ratio estimated was $24 660 US$ per QALY Conclusion Dupilumab is not cost‐effective in Colombia in children between 6 and 11 years old with severe asthma and eosinophilic phenotype. Our evidence should motivate regulatory agencies to improve negotiations for new drugs with better information and evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Dupilumab in children with moderate‐to‐severe asthma: A cost utility analysis

Buendía

Patiño

2022

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this regard, omalizumab, through its mechanism of action, can significantly improve immune functioning in children with allergic asthma. [27][28][29][30] C-ACT scores represent a key assessment tool for evaluating allergic asthma control. Higher C-ACT scores observed in the experimental group indicated more favorable disease control in allergic asthma children.…”

Section: Discussionmentioning

confidence: 99%

Effects of omalizumab combined with budesonide formoterol on clinical efficacy, pulmonary function, immune function, and adverse reactions in children with moderate and severe allergic asthma

Chen

Liang

Chu

et al. 2023

Allergol Immunopathol

View full text Add to dashboard Cite

Objective: To evaluate the clinical efficacy and safety of combining omalizumab with budesonide formoterol to treat children with moderate and severe allergic asthma, and investigate the effect of this combination therapy on pulmonary and immune functions. Methods: The data of 88 children with moderate and severe allergic asthma, who were admitted to our hospital between July 2021 and July 2022, were included in the study. The patients were randomly assigned either to control group (n = 44; received budesonide formoterol inhalation therapy) or experimental group (n = 44; received omalizumab subcutaneous injection + budesonide formoterol inhalation therapy) using computer-generated randomization. The clinical efficacy, asthma control (measured using childhood Asthma-Control Test [C-ACT] score), pulmonary function (forced expiratory volume in 1 s, forced vital capacity, and peak expiratory flow), immune function (cluster of differentiation 3 cells [CD3+ cells], cluster of differentiation 4 cells [CD4+ cells], immunoglobulin G, immunoglobulin A, and immunoglobulin E), and adverse reactions were observed and compared between both groups. Results: After treatment, the experimental group had improved levels of pulmonary function and immune function indexes, higher C-ACT scores, and a higher overall response rate than the control group (P < 0.05). In addition, the incidence of adverse reactions was not significantly different between both groups (P > 0.05). Conclusion: The combination of omalizumab with budesonide formoterol for treating moderate and severe allergic asthma in children demonstrated promising clinical efficacy and improved their pulmonary and immune functions, leading to more rational asthma control. The combined regimen demonstrated satisfactory clinical safety and deserved clinical promotion.

show abstract

“…However, there is still little information about allergic asthma in tropical and developing countries. In addition, there is scarce published information about the clinical use of omalizumab in asthma in Colombia [30][31][32]. This study was aimed to evaluate the real-world effectiveness of omalizumab in this country.…”

Section: Introductionmentioning

confidence: 99%

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia

Torres‐Duque

Ocampo-Gómez²,

Castillo³

et al. 2022

BMC Pulm Med

View full text Add to dashboard Cite

Background The allergic phenotype is responsible for more than 50% of severe asthma cases. In a stepwise approach, add-on treatments such as anti-IgE are used for severe allergic asthma (SAA). This study was aimed to describe the real-world effectiveness of omalizumab in adult and pediatric patients with SAA in Colombia. Methods This was an observational, non-interventional, retrospective study. Data from patients with SAA that received at least one month of treatment with omalizumab was obtained from medical records at eight sites in Colombia. Time-zero (t − 0) was defined as the date of initiation of omalizumab, and data was gathered for a 12-month period before t − 0 and a 12-month period after t − 0. Clinical outcomes, including exacerbations, were assessed at 6 and 12 months. Effectiveness of omalizumab was evaluated in terms of the reduction of the risk of exacerbations (annualized rate). Results We included 143 patients with SAA. There was a decrease of 72.4% of the annualized rate of clinically significant asthma exacerbations during the year after omalizumab (from 1.74 before to 0.48 after) with a substantial reduction of the risk of exacerbations by 56.7% (RR [95% CI] 0.43 [0.30–0.63] p < 0,001). Conclusion The use of omalizumab in Colombia as a treatment for SAA notably reduced the risk of clinically significant exacerbations. This study is the first to evaluate omalizumab real-life effectiveness in pediatric and adult patients in the country.

show abstract

Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma

Cited by 15 publications

References 20 publications

Dupilumab in children with moderate‐to‐severe asthma: A cost utility analysis

Dupilumab in children with moderate‐to‐severe asthma: A cost utility analysis

Effects of omalizumab combined with budesonide formoterol on clinical efficacy, pulmonary function, immune function, and adverse reactions in children with moderate and severe allergic asthma

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia

Contact Info

Product

Resources

About